Collegium posts record Q3 revenue as ADHD growth offsets pain portfolio decline
Collegium Pharmaceutical (COLL) reported record Q3 revenue of $216.3M and kept 2026 guidance, while pain product sales and adjusted EBITDA fell.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Collegium Pharmaceutical (COLL) reported record quarterly revenue for the third quarter of $216.3M, up 3% from a year earlier. The main contributors were higher sales of JORNAY PM and the first full quarter of AZSTARYS under its new ownership.
Revenue and adjusted EBITDA from the pain portfolio declined, while the company reaffirmed its guidance for fiscal 2026. According to TradingView, accelerating ADHD growth was supported by AZSTARYS returning to prescription growth. Pain products remain significant cash generators, but they face payer pressure and generic competition.
why it matters
For investors, the key point is that ADHD growth is offsetting weakness in the pain segment, and the unchanged guidance suggests management still expects its outlook to hold. Payer pressure and generic competition remain the main risks for these products.
market impact
COLL shares: ADHD sales growth offsets the decline in the pain segment
- COLL shares mixed — record revenue and ADHD growth support the stock, while the pain portfolio decline weighs on it
tags
instruments
on polymarket
sources
- COLL: Record revenue and ADHD growth offset pain portfolio and adjusted EBITDA declines — TradingView, 5 November 2026 at 12:34 UTC
- COLL: Record revenue and accelerating ADHD growth offset pressure across the pain portfolio — TradingView, 5 November 2026 at 14:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗